The potential for federal cannabis rescheduling is rightly getting a lot of attention for what it may do to improve the economics of plant‑touching operators. But buried in the recent executive order is a second, potentially overlooked opportunity: the formal integration of CBD into the medical and reimbursement landscape. That angle could be especially important for companies like LEEF Brands, Inc. (CSE: LEEF; OTCQB: LEEEF), which already control large permitted hemp acreage and operate sophisticated extraction infrastructure capable of producing pharmaceutical‑grade cannabinoid ingredients.
Rescheduling and the New CBD Backdrop
On December 18, President Trump signed an executive order directing federal agencies to accelerate the move of marijuana from Schedule I to Schedule III under the Controlled Substances Act. The timing of the potential rescheduling is still subject to the federal rulemaking process. This shift, while not full legalization, would remove cannabis from the most restrictive category, would acknowledge medical use, and is expected to eliminate the punitive 280E tax treatment that has crippled many operators’ cash flows.
The same order contains a second pillar: expanding medical access to cannabidiol, or CBD. CBD is a non-psychoactive ingredient found in cannabis and hemp plants. It directs the Centers for Medicare & Medicaid Services (CMS) Innovation Center to develop a pilot program under which Medicare beneficiaries could receive up to roughly $500 per year in physician‑recommended, hemp‑derived CBD products as early as 2026. In parallel, the administration has signaled a broader re‑examination of hemp‑derived cannabinoids after recent appropriations language threatened to re‑criminalize many full‑spectrum CBD products despite their federal legality under the 2018 Farm Bill.
There is already a significant market among older Americans for CBD products. A recent study indicates about 1 in 7 people 65 years or older report using CBD, and in the 50-64 age group that ratio bumps up to about 1 in 6. There are about 124 million Americans over 50 years of age, so conservatively about 18 million of them are already using CBD in a wildly unregulated market. At the same time, there are about 17 million Americans over the age of 50 receiving Medicaid benefits. Giving them a $500 annual CBD stipend would create an instant and medically-validated market.
Taken together, rescheduling plus a Medicare CBD pilot suggest CBD is starting to be treated less like a wellness fad and more like a legitimate medical input that may be integrated into formal care pathways, at least for specific indications and formulations. That is a very different environment than the largely unregulated, retail‑driven CBD boom of a few years ago, and it plays to the strengths of well‑capitalized, compliant extractors.
Why This Matters for LEEF and the Industry
LEEF’s press release on the executive order hits the obvious positives first: moving cannabis to Schedule III should remove 280E, improve sector cash flows, and lower the cost of capital, especially as more institutional investors and lenders become comfortable with the risk profile. That is a rising‑tide story for the entire licensed cannabis ecosystem.
But for LEEF there is a second, more specific angle: hemp and CBD. The company controls the 1,900‑acre Salisbury Canyon Ranch in California, one of the largest cannabis cultivation projects in the world, with plans to expand licensed cannabis acreage to 187 acres by 2027. On top of that, it holds a dormant 100‑acre hemp permit at the same property, a strategic asset the company has deliberately left on the shelf while regulatory and market conditions for CBD remained murky.
At the same time, LEEF operates what it describes as “world‑class extraction and manufacturing” facilities serving brands in California and New York, producing high‑purity concentrates and ingredients at scale. The infrastructure that today supports THC extraction is, with appropriate process adjustments and compliance controls, well‑suited to producing GMP‑grade CBD and other cannabinoids that could be used in medical or reimbursed products.
If CBD is about to be pulled more fully into the orbit of regulated, medically supervised use—especially within a federal pilot program that will care deeply about quality, consistency, and traceability—it is operators like LEEF, not small, under‑capitalized CBD brands, that are best positioned to supply that demand.
How LEEF Can Capitalize
LEEF’s own commentary emphasizes this optionality. The company notes that it is “closely monitoring federal developments related to hemp‑derived cannabinoids and potential Medicare coverage for certain CBD products” and highlights its 100‑acre hemp permit and extraction platform as strategic assets in that context. In practical terms, that translates into several potential paths:
- Supplying API‑like CBD ingredients to pharmaceutical, nutraceutical, or medical‑product companies participating in the Medicare pilot or similar programs.
- Co‑developing or white‑labeling compliant CBD formulations for partners that do not have internal extraction or bulk processing capabilities.
- Leveraging Salisbury Canyon Ranch’s scale to secure low‑cost, fully traceable hemp biomass under vertically integrated control, improving margins and quality assurance.
Because HHS and CMS will be under pressure to ensure product quality and avoid another “Wild West” CBD landscape—especially with taxpayer dollars in play—vendors that can show rigorous compliance, testing, and track‑and‑trace will have a built‑in advantage. That is an environment where a scaled, audited, multi‑state operator has a meaningful edge over small, undercapitalized players.
Bigger Picture: A More Mature Cannabinoid Landscape
For the broader industry, the potential combination of rescheduling and formal CBD pilots is a sign that U.S. cannabinoid policy may be finally evolving from prohibition‑era patchwork to a more mature, medically grounded framework. Tax relief, better research conditions, and clearer rules for both THC and CBD are likely to:
- Improve profitability and cash generation, especially for operators most burdened by 280E today.
- Encourage more serious clinical and translational research on cannabinoid therapies.
- Shift capital flows toward companies that can operate under more rigid standards
LEEF’s press release makes it clear that management sees both sides of this transition: near‑term financial relief from rescheduling and a longer‑term chance to participate in a regulated, potentially reimbursed CBD market using assets it already controls. For investors, that hemp/CBD angle may offer an overlooked but potentially very fruitful opportunity.
